about
Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantationThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1Ipilimumab and its toxicities: a multidisciplinary approachThyroid hormone inactivation in gastrointestinal stromal tumorsThyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosisHypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare diseaseThe sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.Thyroid Disorders in the Oncology Patient.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.The immunopathogenesis of chronic autoimmune thyroiditis one century after hashimoto.Autoimmune thyroid disease elicited by NY-ESO-1 vaccination.The Brazilian consensus for the diagnosis and treatment of hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Mitigating the toxic effects of anticancer immunotherapy.Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesPathogenesis of Hyperthyroidism.Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region.Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not).Pomalidomide-induced hypothyroidism.Thyroid function in the etiology of fatigue in breast cancer.The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
P2860
Q26827226-FFDEEAB9-C469-4983-944A-9C6238E8A9CCQ28485085-A157DD3B-803C-436A-B026-4078587F1607Q33408049-1D9C4727-63AE-4456-BD2A-764F5916353FQ33658400-F1F9414A-FBE4-49AF-A85D-50F419D604A8Q33777476-38CAB670-F6B6-4B10-B560-53EF7599D934Q34294545-455B40ED-7EC0-4E7D-9990-D1D31C13A25DQ35020386-14CDE848-5C6B-49C9-A090-0A5CA2D73802Q35089364-805E62A4-B6F5-4929-A943-0C79C0C2E189Q35913194-5373774C-9576-4074-A5CF-769BB9163F6BQ36128415-C9367EF7-1E50-416B-9B42-0D9AE1C46C73Q36148873-0F866777-AAA6-4D4D-96F6-EAF0D9A93B42Q36736494-99086FED-7044-4B21-81DF-C07016F4F7DBQ36989101-AFFD2535-CF2E-4007-A70B-D5ED900A033DQ37212903-07D2C9C3-3695-47FF-AF0E-647C393DD39BQ37290942-308AD904-C723-49A3-B0DA-CB90D9EA7A0FQ37587971-0CB2CC1E-AF62-403F-B1CD-47FC7B32537FQ38107399-F0E28E4F-1838-4A32-A2D1-E7B43749FDF4Q38180319-CEE34F50-5D65-4AE5-B721-9160FD216F39Q38558092-7BBDE04D-09CA-4136-BFAF-4A02BB66BF66Q38783026-790BBE55-F8C8-44C2-83D3-41001B4C51D8Q39010566-D0F2541F-BA99-4650-8DFB-A07CF1DCB2E5Q40353489-DE1D90C3-BCD8-4C21-90B7-FFD1F4429126Q41270677-000DD59F-F484-4706-B3D5-0EDCA14D1C32Q45364903-B0AA565E-08E8-4777-8732-E1A6C1ABA6D9Q47157931-F6A42806-2347-41F0-BB1F-C620782E2DCBQ54937435-FA17E8A0-CF55-4C3D-A6A1-BD54BAA66E8EQ57178624-C7C84917-85B4-4CCA-9F32-D7B2AE6F9DBB
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Thyroid dysfunction from antineoplastic agents.
@ast
Thyroid dysfunction from antineoplastic agents.
@en
type
label
Thyroid dysfunction from antineoplastic agents.
@ast
Thyroid dysfunction from antineoplastic agents.
@en
prefLabel
Thyroid dysfunction from antineoplastic agents.
@ast
Thyroid dysfunction from antineoplastic agents.
@en
P2093
P2860
P356
P1476
Thyroid dysfunction from antineoplastic agents.
@en
P2093
Ellen Marqusee
Ole-Petter Riksfjord Hamnvik
P Reed Larsen
P2860
P304
P356
10.1093/JNCI/DJR373
P407
P577
2011-10-18T00:00:00Z